Drugs

Nanotech ‘passport to the brain’ for therapeutics

Researchers discover a new nanotech approach to deliver therapies through the blood-brain barrier. Scientists at Tufts University have discovered a way to deliver therapeutics safely...

SENISCA seeks funding for senescence reversal

University of Exeter spinout raising seed investment as it targets aging aesthetics and age-related disease with ground-breaking rejuvenation technology. Deep in the labs at the...

Fruit fly research could hold key to lifespan

Research carried out on the effects of the drug Mifepristone on fruit flies and roundworms has revealed key findings that could pave the way...

Longevity investment: Apollo aims for the moon

Co-founder of Longevity-focused investment firm shows you can target aging AND appeal to biotech investors. Founded in 2016, Berlin and Boston-based Apollo already boasts an...

Leading academic “profoundly disappointed” by COVID-19 response

Professor Richard Faragher asks why developments in aging research have been largely ignored in the global response to the COVID-19 pandemic. With the world currently...

Exploring the neuroprotective benefits of Longevity drug candidates

Understanding the role aging plays in neurodegenerative diseases could be the key to curing them – or even preventing them with neuroprotective candidates. A team...

Geroscience – Longevity and the COVID-19 upside

New paper examines using a geroscience approach, both in terms of fighting COVID-19 and towards a wider Longevity framework. Geroscience is all about understanding the...

Exclusive interview: Professor Richard Faragher and cellular senescence

With senolytics driving investor interest in the Longevity sector, we speak to Professor Richard Faragher about resveratrol and the potential for rejuvenation of senescent...

Nanoparticles target immune response using red blood cells

Polystyrene nanoparticles deliver drug payload directly to the spleen and bypass lengthy clinical trial requirements. Vaccines are making headlines at the moment, for obvious reasons, ...

Alkahest reveals clinical trial progress

Alkahest pipeline sees multiple therapeutic candidates progressing through clinical trials. Biopharmaceutical company Alkahest has released details of its progress on a range of therapeutic candidates;...

Challenging the one drug/one disease model

A new paper supports the targeting of aging processes, rather than just one disease, to improve Longevity outcomes. Multimorbidity is a challenge for Longevity; defined...

Robotics and AI combine for new therapeutics discovery

Insilico Medicine and Arctoris announce robotics/AI partnership to focus on COVID-19 inhibitors that could have wide-reaching benefits for Longevity. Two companies have joined forces in...

PDL announces results of biological age reduction research

Ponce De Leon Health shares pilot results suggesting that its Rejuvant LifeTabs reduce biological age by an average of 8.5 years. In the pilot, biological...

Easy-peasy Series-B(sy)

Nuritas launches PeptiYouth™ an AI-discovered peptide, clinically proven, anti-aging molecule. Nuritas, a leader in Artificial Intelligence-based peptide discovery, has launched PeptiYouth™, a peptide discovered within peas and which, following clinical trials, has been shown...

Machine learning to de-risk clinical trials

Insilico and Oxford University used machine learning to predict major clinical forms of drug cardiotoxicity. Insilico Medicine announced this week that they, in partnership with...

Novel approach breaks through blood-brain barrier

Molecular transport is on target for shuttling therapies directly into the brain. Like an exclusive nightclub, the brain has the best bouncer in the business....

Move over AI? Here comes biological intelligence

Braincures raising funds to take-on AI drug discovery for Alzheimer’s and other neurological diseases with data analysis and systems biology. The treatment of neurological diseases...

New Japanese stem cell clinical trial for aging frailty

Longeveron announces Phase 2 clinical trial to evaluate the safety and efficacy of Mesenchymal Stem Cells (LMSCs) for the treatment of aging frailty in...

Unlocking the Longevity potential of our oceans

Biologist focuses on the coast of Oman to discover how extreme environments and oceanic life could provide sources for Longevity. With issues like climate change, overfishing...

Alkahest announces phase 2 study treatment of cognitive impairment

Extra-corporeal medical device could improve neuro outlook for end-stage renal disease patients. Alkahest has announced its first foray into dialysis-associated dementia with a new randomised,...

Latest articles

Selfie biomarkers: AI and insurtech implications for Longevity

AI firm Lapetus targets the face as a biomarker of aging: one simple picture can open-up a host of opportunities and implications. Wow. Named after...

Low levels of stress hormone contributes to aging

When it comes to the stress hormone cortisol, balance is everything, according to a new study in Germany.  There have been plenty of studies that...

Rejuvenation Roadmap charts life extension progress

We take a trip down Lifespan.io's Rejuvenation Roadmap – and it's a journey towards Longevity progress. Lifespan.io is a US-based non-profit organisation that seeks to...

Longevity therapies delivered through skin is a topical issue

Non-invasive therapy that comes in a bottle could be the Longevity crème de la crème. Therapeutic substances like arnica, turmeric and witch hazel have been...